pharmaceutical-investing Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111
Eloxx Pharmaceuticals Announces FDA Grant of Orphan-Drug Designation for Investigational Drug ELX-02 for Treatment of Cystinosis
pharmaceutical-investing Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma
pharmaceutical-investing Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
pharmaceutical-investing Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X Syndrome
pharmaceutical-investing Proteostasis Therapeutics Announces FDA Grants Orphan Drug Designation for PTI-428 in Cystic Fibrosis
pharmaceutical-investing Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency
pharmaceutical-investing ContraVir Pharmaceuticals Announces TXL Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population
U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
Strongbridge Biopharma Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris
Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent
